

# Quality assessment of platelet rich plasma during anti-platelet therapy\*

Chad W Smith<sup>1</sup>, Robert S Binford<sup>2</sup>, David W Holt<sup>3</sup> and David P Webb<sup>4</sup>

<sup>1</sup>Tennessee Perfusion Services, PLLC, Centennial Medical Center, Cardiothoracic Surgery, Nashville, Tennessee, USA. Graduate Degree Completion Program, School of Allied Health Professions, University of Nebraska Medical Center, Omaha, Nebraska, USA;

<sup>2</sup>Centennial Medical Center, Cardiothoracic Surgery, Nashville, Tennessee, USA;

<sup>3</sup>Program Director Graduate Degree Completion, School of Allied Health Professions, University of Nebraska Medical Center, Omaha, Nebraska, USA;

<sup>4</sup>Director of Perfusion Services, Vanderbilt Medical Center, Nashville, Tennessee, USA

Platelet rich plasma (PRP) is being used with increased frequency in many surgical procedures for its known benefits of accelerated surgical wound site healing. Speculations in its efficacy in the presence of anti-platelet therapy have been proposed. To aid in defining a quality platelet rich plasma product in the presence of acetylsalicylic acid (ASA) and Plavix (clopidogrel bisulfate), we investigated three (3) groups (n=18) of cardiac surgical patients receiving PRP. Platelet function test, platelet concentration, and quantification of growth factors (PDGF-bb and TGF-b1) were evaluated. Results showed no statistical

evidence of decreased growth factors delivered to the surgical wound site in the presence of acetylsalicylic acid (ASA) and/or Plavix (clopidogrel bisulfate). Evidence in this pilot study supports the use of PRP for patients receiving Plavix and aspirin therapy without compromising the quantity of specific growth factors delivered to a wound site. *Perfusion* (2007) 22, 41–50.

**Key Words:** Platelet Rich Plasma, Plavix, Aspirin, PDGF-bb, TGF-b1